Applicability of [11C]PIB micro-PET imaging for in vivo follow-up of anti-amyloid treatment effects in APP23 mouse model

Publication date: Available online 15 May 2017
Source:Neurobiology of Aging
Author(s): Anniina Snellman, Johanna Rokka, Francisco R. Lopez-Picon, Semi Helin, Francesca Re, Eliisa Löyttyniemi, Rea Pihlaja, Gianluigi Forloni, Mario Salmona, Massimo Masserini, Olof Solin, Juha O. Rinne, Merja Haaparanta-Solin
In this study, we evaluated the anti-amyloid effect of functionalized nanoliposomes (mApoE-PA-LIP) in a mouse model of Alzheimer's disease (AD) with use of positron emission tomography (PET) and β-amyloid (Aβ) targeted tracer [¹¹C]PIB. APP23 mice were injected with mApoE-PA-LIP or saline (3 times per week for three weeks) and [¹¹C]PIB imaging was performed at baseline, after the treatment and after three months follow-up period, accompanied by Aβ immunohistochemistry and ELISA. After the treatment, [¹¹C]PIB binding ratios between mApoE-PA-LIP and saline groups were equivalent in all analyzed brain regions; However, in the saline group, binding ratios increased from the baseline, whereas no increase was detected in the mApoE-PA-LIP group. During the additional follow-up, [¹¹C]PIB binding increased significantly from baseline in both groups, and binding ratios correlated with the immunohistochemically defined Aβ load. This study further supports the use of [¹¹C]PIB PET imaging as a biomarker of Aβ deposition in APP23 mice, and highlights the benefits of non-invasive follow-up, i.e. using baseline data for animal stratification and normalization of treatment effects to baseline values, for future anti-amyloid treatment studies.

Graphical abstract

http://ift.tt/2rbQOOx